Last reviewed · How we verify
AL003
AL003 is a monoclonal antibody that activates TREM2 signaling on microglia to promote neuroinflammatory resolution and clearance of pathogenic proteins in the central nervous system.
AL003 is a monoclonal antibody that activates TREM2 signaling on microglia to promote neuroinflammatory resolution and clearance of pathogenic proteins in the central nervous system. Used for Alzheimer's disease.
At a glance
| Generic name | AL003 |
|---|---|
| Sponsor | Alector Inc. |
| Drug class | TREM2 activator monoclonal antibody |
| Target | TREM2 |
| Modality | Biologic |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
AL003 binds to TREM2 (triggering receptor expressed on myeloid cells 2) on microglial cells, enhancing their phagocytic capacity and shifting them toward a neuroprotective phenotype. This activation promotes clearance of amyloid-beta and tau pathology while reducing neuroinflammation, potentially slowing neurodegeneration in Alzheimer's disease and other neurodegenerative conditions.
Approved indications
- Alzheimer's disease
Common side effects
- Amyloid-related imaging abnormalities (ARIA)
- Infusion reactions
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |